Authors

LAG-3 Fills a Complex Role in the Immune System

The LAG-3 pathway has emerged as the next target for the use of immune checkpoint inhibitors in oncology.

PARP Inhibitor Therapy Options Are Transforming Landscape in Ovarian Cancer

PARP inhibitors have fundamentally changed our therapeutic algorithms in ovarian cancer, even as their use continues to evolve.

Dr Swoboda on the Role of TKIs in Chronic Myeloid Leukemia

David M. Swoboda, MD, discusses the roles of available TKIs for the treatment of patients with chronic myeloid leukemia.

Whole Genome Sequencing for AML/MDS Risk Stratification

Two clinical trials for AML or MDS are open and enrolling at Siteman Cancer Center and Washington University School of Medicine in St. Louis.

Location Matters: US Patients With Adult T-Cell Leukemia/Lymphoma Have Distinct Clinical, Genetic Features

Adult T-cell leukemia/lymphoma is a rare and very aggressive T-cell neoplasm with an extremely poor prognosis. It is also the only human cancer caused by a retrovirus—human T-cell leukemia virus.

Roswell Park Team Provides First Direct Evidence of CD28 Effects on CAR T-Cell Therapy

The FDA-approved drug abatacept may improve treatment responses and prevent some immune AEs associated with CAR T-cell therapy.

Zavabresib Nets FDA Orphan Drug Designation for Myelofibrosis

The FDA has granted orphan drug designation to zavabresib for the treatment of patients with myelofibrosis.

A Prayer for a More Equitable Future

Russell J. Ledet, PhD, discusses being a Black man in the field of oncology.

The Mullin Sisters

A breast surgical oncology fellow tells the story of how 3 women in his family helped shape his career and provide a purpose for his passion.

Raising the Bar in the First-Line Treatment of EGFR+* mNSCLC Advanced Lung Cancer

Taking Back Our Empathy: Reflections on a New Model of Medical Education

Bharat Sanders sheds light on how patient-centered medical education put him behind the eyes of the patient and fundamentally changed the way he practices medicine.

Extending the Frontiers of Checkpoint Inhibition in Merkel Cell Carcinoma

In the treatment of unresectable or metastatic Merkel cell carcinoma, immune checkpoint inhibitors have activity and tolerability.

Make Time for Your Own Health

Although graduate medical education at many hospitals includes provisions to ensure that trainees remain physically, emotionally, and mentally healthy, few residents and fellows make use of these resources.

Undocumented Immigrants With Cancer Face Unique Care Challenges

Undocumented immigrants continue to face discriminatory policies, which affect those with cancer on emotional, financial, physical, and social levels.

Managing TLS and CRS/ICANS: Through the Lens of a First-Year Hematology/Oncology Fellow

Tumor lysis syndrome is an oncologic emergency that every clinician will likely encounter at one time or another, and managing it requires careful consideration of a number of factors.

Reducing Burnout Requires an Organizational Response

A new study suggests that reducing physician burnout requires an organizational-level response that focuses on creating of a medical practice culture that value qualities such as teamwork, open communication, and process improvement.

How to Make Clinical Decisions With AI in Oncology

Speculation on the impact of large language models or artificial intelligence in the future of health care is commonplace, causing excitement and concern.

Physicians Must Become Advocates to Play a Role in Community Oncology’s Future

Although some community oncologists may think they can do little to abate the reimbursement reform forces that are affecting their practices, there are actions they can, and should, take to influence the success of their value-based care journey that may not be part of the fundamentals of their current practice.

LSU LCMC Health Cancer Center Researchers Uncover Key Immune Differences in Triple-Negative Breast Cancer

A LSU LCMC Health Cancer Center study provides new insights that could lead to more effective, personalized treatments in TNBC.

Dr Wang on Updated Efficacy and Safety Data With First-Line Ivonescimab Plus Chemotherapy in TNBC

Xiaojia Wang, MD, shares responses achieved with the combination of ivonescimab plus chemotherapy in locally advanced unresectable or metastatic TNBC.

Mentoring Oncologists in the Era of Social Distancing

Mentoring is critically important to the development of young academic hematology/oncology trainees.

Bringing Precision Medicine to Community Oncology is Going to Require Bigger Thinking

Immunotherapy Paves Path for New Standards of Care in Gastroesophageal Cancers

It is crucial to understand and interpret the results from the landmark clinical trials in the context of recent FDA approvals in gastroesophageal cancers.

Best Practices for Virtual Conference Presentations

As the autumn and winter conference season approaches, Curtis Lachowiez, MD, reflects on the impact 2020 left on the field of oncology.

Allogeneic Transplant and Gene Therapy in Sickle Cell Disease

Markus Y. Mapara, MD, PhD, of Columbia University Irving Cancer Center, discusses the use of allogeneic transplant and gene therapy for patients with sickle cell disease.

Palliative Care for Young Adults Is a Growing Reality in CRC

Although most younger patients received diagnoses of cancer of the rectum or distal colon, incidence rates are increasing across all colorectal anatomic subsites.

It’s Time to Address Patient Needs: The Changing Landscape of Colorectal Cancer Treatment

Demystifying the Role of Palliative Care in the Oncology Clinic

Despite American Society of Clinical Oncology guidelines calling for introduction of palliative care early in the course of disease, these services remain underused.